4 completed, 3 active not recruiting, 2 terminated, 1 recruiting. 7 Phase 2, 4 Phase 1, 1 Early Phase 1, 1 Not applicable.
Follow Stage IVB Colon Cancer AJCC v8: new trials by email Literature Review of Stage IVB Colon Cancer AJCC v8 trials Research Report on Stage IVB Colon Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery NBT-NM108 - Metastatic Colon Carcinoma, Stage IV Colon Cancer AJCC v8 | Phase 2 | Recruiting | Howard S. Hochster, MD | 42 | 2022-05-03 | 2026-01-06 |
| Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events Best Practice, Patient Monitoring, Questionnaire Administration - Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8 | Not applicable | Active not recruiting | M.D. Anderson Cancer Center | 750 | 2021-05-12 | 2026-06-16 |
| 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases Computed Tomography, 18F-FMAU, Multiparametric Magnetic Resonance Imaging - Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Early Phase 1 | Completed | University of Southern California | 10 | 2021-02-15 | 2024-05-24 |
| LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer Abemaciclib, Cetuximab, ERK1/2 Inhibitor LY3214996 - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 46 | 2020-12-02 | 2026-10-05 |
| SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial CXCR1/2 Inhibitor SX-682, Nivolumab - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 51 | 2020-10-14 | 2026-07-20 |
| Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer Ipilimumab, Nivolumab, Regorafenib - Advanced Colon Adenocarcinoma, Metastatic Colon Adenocarcinoma | Phase 1 | Completed | City of Hope Medical Center | 39 | 2020-05-27 | 2026-01-28 |
| Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer Panitumumab, Quality-of-Life Assessment, Questionnaire Administration - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 2 | Unknown | Academic and Community Cancer Research United | 12 | 2020-04-24 | 2024-05-21 |
| Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial Genetic Testing - Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma | Terminated | Academic and Community Cancer Research United | 199 | 2020-04-20 | 2025-08-29 | |
| TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study Irinotecan, Bevacizumab, Trifluridine and Tipiracil Hydrochloride - Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 42 | 2019-12-27 | 2026-02-10 |
| Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer Savolitinib - Colorectal Carcinoma, Metastatic Colon Adenocarcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2019-07-25 | 2023-10-17 |
| M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability Anti-PD-L1/TGFbetaRII Fusion Protein M7824 - Colon Adenocarcinoma, High-Frequency Microsatellite Instability | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 4 | 2018-03-07 | 2024-11-27 |
Colonic Neoplasms (11) · Rectal Neoplasms (9) · Colorectal Neoplasms (7) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Esophageal Neoplasms (1) · Gastrointestinal Neoplasms (1) · Glioma (1) · Lung Neoplasms (1) · Melanoma (1) · Microsatellite Instability (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1)
Colonic Diseases (11) · Digestive System Diseases (11) · Digestive System Neoplasms (11) · Gastrointestinal Diseases (11) · Intestinal Diseases (11) · Intestinal Neoplasms (11) · Neoplasms (11) · Neoplasms by Site (11) · Gastrointestinal Neoplasms (10) · Rectal Diseases (9) · Colorectal Neoplasms (4) · Adenocarcinoma (2) · Carcinoma (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2)
Nivolumab (2) · Trifluridine (2) · regorafenib (2) · trifluridine tipiracil drug combination (2) · 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine (1) · Bevacizumab (1) · CTLA-4 Antigen (1) · Cetuximab (1) · Disulfides (1) · Genetic Testing (1) · Ipilimumab (1) · Irinotecan (1) · LY3214996 (1) · Magnetic Resonance Spectroscopy (1) · Panitumumab (1)
M.D. Anderson Cancer Center (4) · Academic and Community Cancer Research United (2) · City of Hope Medical Center (1) · Howard S. Hochster, MD (1) · National Cancer Institute (NCI) (1) · Roswell Park Cancer Institute (1) · University of Southern California (1)
United States (11)
John H Strickler (3) · Alisha Bent, MD (1) · Christine M Parseghian, MD (1) · Christos Fountzilas, MD (1) · Hossein Jadvar, MD (1) · Howard S Hochster, MD (1) · Marwan G Fakih (1) · Ryan W Huey, MD (1) · Van K Morris, MD (1)
PMID 33109741, PMID 36821818, PMID 36892833, PMID 39244627, PMID 39652198
P30CA015083 (2), P30CA014089 (1), R01CA187238 (1), UM1CA186704 (1)